Pharmaguy's Insights Into Drug Industry News
181.4K views | +6 today
Follow
Pharmaguy's Insights Into Drug Industry News
Pharmaguy curates and provides insights into selected drug industry news and issues.
Curated by Pharma Guy
Your new post is loading...
Your new post is loading...
Scooped by Pharma Guy
Scoop.it!

Botox - the Duct Tape/Swiss Army Knife of Drugs - Approved for Forehead Lines

Botox - the Duct Tape/Swiss Army Knife of Drugs - Approved for Forehead Lines | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Allergan’s Botox, which the company has called a “pipeline in a drug,” has delivered again.

On Tuesday, the FDA approved the blockbuster product to temporarily improve the appearance of certain forehead lines in adults. The green light marked the med’s third cosmetic indication—it also bears go-aheads to treat crow’s feet and glabellar lines—and makes it the only neurotoxin that can boast approvals in three separate facial treatment areas.

The approval presents another opportunity for Allergan in an aesthetics market that company CEO Brent Saunders has called the best market in the world.

“It's high-quality, it's cash-pay, it's global,” he said on this summer’s second-quarter earnings call. “We are just at the initial stages of market development in the U.S. and almost every market in the world. So we have very high conviction around the sustainability,” he added.

 

Further Reading:

  • “Allergan CEO Brent Saunders is Not Just a Botox Fan, He's Also a Botox User!”: http://sco.lt/4jUjmD
  • Botox, the Swiss Army Knife of Drugs, Featured on Cover of Time Magazine”; http://sco.lt/56XOfB
more...
No comment yet.
Scooped by Pharma Guy
Scoop.it!

Botox Keeps Giving: Allergan's Answer to Duct Tape & Lifetime Profits

Botox Keeps Giving: Allergan's Answer to Duct Tape & Lifetime Profits | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Botulinum toxin, otherwise known as Botox, is used for medical conditions such as severe underarm sweating and chronic migraines.


Allergan, the pharmaceutical company that makes Botox, is in friendly discussions to be acquired by pharma giant Pfizer.


If the merger goes through, it would quite possibly be the biggest of 2015 — Allergan has a market cap of $117 billion, and Pfizer is worth over $200 billion. 


One of the reasons Allergan is worth so much is Botox, which had more than $2 billion in salesas of 2013.


One of the most common pharmaceutical products, Botox is currently known as an anti-wrinkle treatment. However, the drug has many other approved medical uses..

Pharma Guy's insight:

“We see it as a molecule that keeps on giving. As we understand it more, it gives us new ideas of how to use it,” says Dr. Mitchell F. Brin, a neurologist who is the chief scientific officer for Botox at Allergan, the drug’s maker.

 

You may be interested in reading this: "Allergan Doesn't Comply with PhRMA Guidelines, Wins Kudos Anyway"; http://bit.ly/I20Rp9 

more...
No comment yet.
Scooped by Pharma Guy
Scoop.it!

"Brotox": Allergan Bets Narcissistic Young Dudes Will Want Botox

Fine lines. Double chins. Sagging skin. Allergan Plc is betting that these byproducts of aging are becoming an obsession for men.


While women still supply most of the demand for cosmetic drugs, Allergan is betting that by marketing to men, it can squeeze more growth out of well-known drugs such as Botox and create new markets with treatments like Kythera’s Kybella, for double chins.


Call it the “Brotox” strategy.


“We’re starting to see signs of life about men being more open about talking to a doctor about aging,” Allergan Chief Executive Officer Brent Saunders said in an interview before the Kythera deal was announced. He said it would be a “home run” to get men to represent about 20 percent to 25 percent of the U.S. facial aesthetic market, up from 13 percent today.


Men are more reluctant than women to make cosmetic changes to their faces, in part because of concerns they’ll come out looking strange, said David Alessi, a plastic surgeon in Beverly Hills, California.


“Men coming in are just normal dudes and they want to continue looking like normal dudes, just a little bit younger,” he said.

Pharma Guy's insight:

In early January Brenton “Brent” Saunders, CEO of Allergan, had a plastic surgeon pierce his face 30 times, delivering needles full of Botox to the crooks of his eyes and nose. “I don’t have any crow’s feet anymore, and I don’t have any wrinkle lines above my nose,” says Saunders, who was boyish-looking even before his face was shot up with treatments. “Now I can say I’m not just the CEO, I’m a user.”


Talk about drinking your own Kool-Aid!

more...
No comment yet.
Scooped by Pharma Guy
Scoop.it!

Botox, the Swiss Army Knife of Drugs, Featured on Cover of Time Magazine

Botox, the Swiss Army Knife of Drugs, Featured on Cover of Time Magazine | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Though it’s best known for smoothing wrinkles, Botox, which is derived from one of the most deadly toxins known to man, has repeatedly stunned the medical community for its seemingly endless applications. Though the drug is approved for nine medical conditions and several cosmetic ones, Allergan, the company that owns Botox, holds close to 800 more patents for potential uses of the drug. Since it was approved nearly 30 years ago, Botox has indeed become a staple of cosmetic enhancement, but today, more than half of its revenue comes from its therapeutic uses for conditions as varied as chronic migraines and back pain to excessive sweating and twitching eyelids.

 

The off-label use of this particular toxin has helped turn Botox into a blockbuster, as TIME reports in an in-depth cover story. Here are some of the most intriguing uses for Botox… More…

 

Further Reading:

Pharma Guy's insight:

I wonder if Allergan purchased an ad for Botox in this issue.

more...
chirurgien-visage-tunisie's curator insight, February 21, 2017 2:49 AM

Chirurgie esthétique du visage en Tunisie , injection Botrox, injection acide hyaluronique : le couteau Suisse de la chirurgie esthétique . Medespoir une agence de tourisme médical spécialisée

chirurgien-visage-tunisie's comment, February 21, 2017 2:51 AM
je confirme
Scooped by Pharma Guy
Scoop.it!

Pfizer Pins Future on Selling Botox to Men After Viagra Goes Generic

Pfizer Pins Future on Selling Botox to Men After Viagra Goes Generic | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Pharmaceutical giant Pfizer, which employs over 3,000 people in Ireland, recently approached Botox-maker Allergan to discuss what could be the biggest takeover deal this year, the Wall Street Journal said on Wednesday, citing people familiar with the matter.


The healthcare sector has seen an unprecedented wave of deals since early 2014, from large drugmakers buying up smaller rivals, to consolidation among makers of generic medicines and tie-ups between insurers.


A bid for Allergan, which has a market value of $113 billion, would be Pfizer’s second attempt to acquire a European rival, following its unsuccessfully courtship last year of Anglo-Swedish pharmaceuticals group AstraZeneca.


Allergan would give Pfizer, whose revenues are expected to slide 3.3 per cent this year, a boost in top-line growth. The Botox-maker’s revenue is seen increasing 39 per cent this year, according to Thomson Reuters I/B/E/S estimates.

Pharma Guy's insight:

In early January Brenton “Brent” Saunders, the chief executive of upstart pharmaceutical giant Actavis , reclined in a medical chair on a stage in an Orlando hotel ballroom as a plastic surgeon pierced his face 30 times, delivering needles full of Botox to the crooks of his eyes and nose and injecting Juvederm Voluma, a dermal filler, into his cheeks. A cameraman documented every prick and projected it on a huge screen behind him. These are bestselling products for AllerganAGN +0.38%, which Actavis is buying for $67 billion, the biggest health care deal in six years. The audience, 1,000 Allergan sales reps, went wild.


“I don’t have any crow’s feet anymore, and I don’t have any wrinkle lines above my nose,” says Saunders, who was boyish-looking even before his face was shot up with treatments. “Now I can say I’m not just the CEO, I’m a user.”

more...
No comment yet.
Scooped by Pharma Guy
Scoop.it!

$ACT CEO Brent Saunders is Not Just a Botox Fan, He's Also a Botox User!

$ACT CEO Brent Saunders is Not Just a Botox Fan, He's Also a Botox User! | Pharmaguy's Insights Into Drug Industry News | Scoop.it

In early January Brenton “Brent” Saunders, the chief executive of upstart pharmaceutical giant Actavis , reclined in a medical chair on a stage in an Orlando hotel ballroom as a plastic surgeon pierced his face 30 times, delivering needles full of Botox to the crooks of his eyes and nose and injecting Juvederm Voluma, a dermal filler, into his cheeks. A cameraman documented every prick and projected it on a huge screen behind him. These are bestselling products for AllerganAGN +0.38%, which Actavis is buying for $67 billion, the biggest health care deal in six years. The audience, 1,000 Allergan sales reps, went wild.


“I don’t have any crow’s feet anymore, and I don’t have any wrinkle lines above my nose,” says Saunders, who was boyish-looking even before his face was shot up with treatments. “Now I can say I’m not just the CEO, I’m a user.”

Pharma Guy's insight:


I love those "freedom of expression..." Botox ads, that exclaim "Don't hold back! Express it all!" The copy writers certainly didn't hold back on the exclamation points!!


The not-so-subtle subliminal message is "despite what has been reported in the press and on blogs by patients (see "Botox Banality Not a Boon for TV Sitcoms"), use of Botox does not limit your range of facial expressions." But it looks like Saunders has a poker face, which I envision will not change no matter in what direction the Actavis stock price goes.

more...
No comment yet.